Recent studies have demonstrated the dual pro-/antitumor of CXCR3 in various cancers, including in melanoma, breast cancer, and renal cell carcinoma [9, 52]. The gene discussed is CXCR3; the disease is hereditary clear cell renal cell carcinoma.